The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet

Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative bioavailability and food effect of five experimental fixed-dose combination (FDC) tablet formulations of DTG/RPV. Wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Rashmi, Piscitelli, Joseph, Wolstenholme, Allen, Fu, Caifeng, Crauwels, Herta, Wynne, Brian, Adkison, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292371/
https://www.ncbi.nlm.nih.gov/pubmed/32607002
http://dx.doi.org/10.2147/CPAA.S250751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292371/
https://www.ncbi.nlm.nih.gov/pubmed/32607002
http://dx.doi.org/10.2147/CPAA.S250751

Ejemplares similares